Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised medicine.
Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions (56 drug combinations x 20 replicates) on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments. This research, incorporating fundamental science alongside clinical expertise at Aachen University Hospital, was led by EMBL group leader Christoph Merten and Julio Saez-Rodriguez, former group leader at EMBL-EBI and now Professor at Heidelberg University.
Small biopsies, many drugs
Directly testing multiple cancer drugs on biopsies – parts of the tumour which have been taken from a patient – is a powerful way to discover which drugs work best, and for whom. This is because depending on the specific tumour characteristics, cancer therapies can be more effective in some people than others. However, large-scale patient specific drug screenings have so far been limited by the small biopsy size that can typically be obtained from patients. That is why in the current paper, the team developed a miniaturised device which can test more drugs on a limited number of cells.
The research team initially tested 56 drug combinations on two different human cancer cell types grown in the lab. Drug combinations which killed both types of cancer cells were thought to be potentially toxic and thus unsafe for further testing. However, some drug combinations which targeted and killed only one type of cancer cell were found to be more effective than standard clinical therapies which only use one drug. These results were highly reproducible and could be validated in mouse models of human cancer.
Subsequently, cells from four cancer patient biopsies were applied to the microfluidic device and different drug combinations were tested. “We found that each individual cancer responded best to a different combination of drugs, highlighting the urgent need for patient-specific therapies,” says Federica Eduati, joint first author on the paper alongside Ramesh Utharala who designed and developed the microfluidic device.
“Before we transfer this technology into the clinics, we need to repeat these experiments in larger-scale mouse studies to understand which types of cancer this technology works best in,” says Christoph Merten. “Still, this is an exciting ‘proof of principle’ collaboration between scientists and clinicians, and we have shown that these tests can be run quickly and for less than $150 USD per patient.”
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Personalized Medicine: The Trend That's Sweeping Health Careon September 4, 2019 at 6:32 am
From cloud-based medical imaging platforms to artificial intelligence-powered diagnostics, health care continues to be the epicenter of digital innovations that are geared toward boosting patient care ...
- Editas Medicine: A Good Proxy For The Gene Editing Spaceon September 3, 2019 at 10:04 pm
Today, we take an in-depth look at Editas Medicine. While years away from potential commercialization, it is an intriguing name in the emerging gene editing space. A full investment analysis of ...
- Personalized treatment for ARDS: Ready for prime time?on September 3, 2019 at 1:12 pm
Real-world implications Overall, the LIVE study, which is the first to truly evaluate precision medicine in ARDS ... very different and we do not yet have the power determine whether personalized ...
- $175+ Million Microtomes Market - Global Forecast to 2024: Growing Focus on Personalized Medicine - ResearchAndMarkets.comon September 3, 2019 at 2:16 am
Also, the increasing focus on personalized medicine and the emerging economies are offering growth opportunities for players in the microtomes market. However, a lack of skilled professionals to ...
- Precision electronic medicine in the brainon September 2, 2019 at 8:13 am
Ultimately, these personalized electronic therapies will provide new treatment modalities for neurodegenerative and neuropsychiatric illness; powerful control of prosthetics for restorative function ...
- Viewpoint: Strategic use of big data will unlock the potential of precision medicineon August 30, 2019 at 12:39 pm
Should these goals be achieved, big data has the potential to lead to major breakthroughs in precision medicine, providing personalized diagnoses and treatment options and creating "a greater focus on ...
- Personalized mechanical ventilation fails to reduce mortality in ARDSon August 30, 2019 at 6:26 am
Promise of personalized medicine In a linked comment, Carolyn M. Hendrickson, MD, MPH, and Carolyn S. Calfee, MD, MAS, placed the findings into context. “The results of this trial highlight both the ...
- Liquid biopsy imporves personalized medicine for canceron August 30, 2019 at 2:40 am
A new liquid biopsy medical technique promises to take personalized medicine for cancer into the future, offering better treatment options with treatment based on real-time data assessments. The key ...
- Direct Primary Care Offers Cost Savings, Privacy, Personalized Careon August 29, 2019 at 10:29 pm
Singleton: More and more studies show, and the Kaiser Family Foundation did a big study where they asked patients what they wanted out of their medical visits, and what they found was that ...
via Bing News